Champions Oncology (CSBR) Cash from Operations (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Cash from Operations of 1998000.0 for Q2 2026, down 129.09% year-over-year from 6868000.0 in Q2 2025, and down 49.22% quarter-over-quarter from 1339000.0 in Q1 2026.
Champions Oncology (CSBR) Cash from Operations (2010 - 2026) Analysis & Trends
Champions Oncology's Cash from Operations history runs 17 years deep, the most recent figure standing at 1998000.0 for Q2 2026.
- In Q2 2026, Cash from Operations fell 129.09% year-over-year to 1998000.0; the TTM figure through Apr 2026 stood at 4472000.0 (down 160.55% YoY), while the FY2026 annual figure was 4472000.0, down 160.55% from the prior year.
- Cash from Operations for Q2 2026 stood at 1998000.0, down from 1339000.0 in the prior quarter.
- The five-year high for Cash from Operations was 6868000.0 in Q2 2025, with the low at 3991000.0 in Q3 2023.
- The 5-year median for Cash from Operations is 58000.0 (2022), against an average of 322333.33.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations surged 3053.33% in 2022, then tumbled 1946.67% in 2023.
- Champions Oncology's Cash from Operations stood at 3286000.0 in 2022, then tumbled by 82.08% to 589000.0 in 2023, then slumped by 148.05% to 283000.0 in 2024, then plunged by 513.07% to 1735000.0 in 2025, then fell by 15.16% to 1998000.0 in 2026.
- Business Quant data shows CSBR's Cash from Operations at 1998000.0 in Q2 2026, 1339000.0 in Q1 2026, and 1735000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn | -2.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -2.00 Mn |
| Apr 30, 2026 | -2.00 Mn |
| Jan 31, 2026 | -1.34 Mn |
| Jan 31, 2026 | -1.34 Mn |
| Oct 31, 2025 | -1.74 Mn |
| Oct 31, 2025 | -1.74 Mn |
| Jul 31, 2025 | 600,000.00 |
| Jul 31, 2025 | 600,000.00 |
| Apr 30, 2025 | 6.87 Mn |
| Apr 30, 2025 | 6.87 Mn |
| Jan 31, 2025 | 490,000.00 |
| Jan 31, 2025 | 490,000.00 |
| Oct 31, 2024 | -283,000.00 |
| Oct 31, 2024 | -283,000.00 |
| Jul 31, 2024 | 311,000.00 |
| Jul 31, 2024 | 311,000.00 |
| Apr 30, 2024 | -1.82 Mn |
| Apr 30, 2024 | -1.82 Mn |
| Jan 31, 2024 | -919,000.00 |
| Jan 31, 2024 | -919,000.00 |